Canopy Growth Corp (NYSE: CGC) and Sequential Brands Group, Inc. (NASDAQ: SQBG) will be working together on a line of CBD products. As part of the collaboration, renowned entrepreneur Martha Stewart will join Canopy Growth.
Martha Stewart will take an advisory role at Canopy Growth. The company will rely on her knowledge of consumer products, while developing their own line of CBD products across various categories.
Sequential Brands Group owns a portfolio of brands including Martha Stewart Living Omnimedia, a diversified media and merchandising company.
Canopy Growth didn't say when first products will hit the shelves, but Martha Stewart said the first collaboration with Canopy Growth will focused on a line of products for pets.
The Cannabis Capital Conference is coming back to Toronto! Click here to learn how you can join Tim Seymour, Jon Najarian, Danny Moses, Alan Brochstein and many others.
Why It's Important
Recently, Canopy Growth announced it's entering the U.S. hemp market. The company received a license to cultivate hemp in the state of New York and said it will invest between 0 and 0 million in a hemp industrial park in the state. In an interview with Yahoo Finance earlier this month, Canopy CEO Bruce Linton said the company will increase the investment amount to $500 million and will establish operations in more states.
Developing a line of hemp-derived CBD products in collaboration with Martha Stewart will give Canopy Growth an edge, given Stewart's acclaimed recognition as a businesswoman, media person, book author, and lifestyle expert.
Canopy Growth traded higher by 4.4 percent to $47.69 per share Thursday morning, while Sequential Brands traded up 22.5 percent to $1.47 per share.
Martha Stewart Touts Detroit As 'A Hotbed Of Innovation'
Cannabis Companies Beginning To Ante Up For Bets On Hemp
Photo by Dustin Blitchok: Martha Stewart speaks at Alibaba's Gateway '17 conference at Cobo Center in Detroit.
See more from Benzinga
- NYSE Gets Another Cannabis Company, CannTrust To Make Debut Feb. 25
- Canopy Growth's Q3 Revenue Jumps 283% Year-Over-Year
- MediPharm Signs .38M Cannabis Oil Deal
© 2019 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.